Concepedia

H.H. Sedlacek

HS

Statistics

Publications

5

Citations

636

H-Index

5

Active since

1983

Affiliations

National Cancer Institute(Current)

H.H. Sedlacek is an author at National Cancer Institute specializing in pharmacology, medicine, and cyclin-dependent kinases.

Publications per year

1983–1999

5

Publications

5

Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy

H.H. Sedlacek, Jörg Czech, Ramachandra Naik et al. · International Journal of Oncology · 1996 · 277 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Elevated expression of endoglin, a component of the TGF-?-receptor complex, correlates with proliferation of tumor endothelial cells

Daniel W. Miller, Wolff Graulich, Bernadett Karges et al. · International Journal of Cancer · 1999 · 197 citations · Full text

Medicine, Cell Biology, Oncology +8

Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.

H. U. Schorlemmer, Klaus Bosslet, H.H. Sedlacek · PubMed · 1983 · 74 citations

Life Sciences, Immunology, Pharmacology +11

Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver

Walter Jäger, Bettina Zembsch, Peter Wolschann et al. · Life Sciences · 1998 · 71 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

The Change in Research for the Therapy of Tumors

H.H. Sedlacek, Dieter Hoffmann, Jörg Czech et al. · CHIMIA International Journal for Chemistry · 1991 · 17 citations · Full text

Medicine, Cancer Biology, Oncology +10

1–5 of 5